 phase i-ii trial pentoxifyllin prevent transplant-rel toxic bone marrow transplant diseas relaps transplant toxic applic bone marrow transplant bmt treatment hematolog malign elev level tumor necrosi factor alpha tnf-alpha develop transplant complic phase i-ii trial pentoxifyllin ptx xanthin deriv capabl down-regul tnf-alpha product patient hematolog malign bmt thirti consecut adult patient median age allogen autolog bmt patient dose level mg/d day day posttranspl ptx signific advers side effect dose level actuari day surviv patient confid interv good risk control group ptx experienc mucos day hepat venocclus diseas incid renal insuffici day total parenter nutrit tpn hospit control day addit incid graft-versus-host diseas gvhd equal II ptx recipi ptx dose excess mg/d sever mucos tpn requir hospit discharg patient mg/d ptx studi oral administr ptx mg/d reduct morbid mortal patient undergo bmt prospect random trial progress preliminari observ